Identification of Appropriate Endogenous Biomarker for Risk Assessment of Multidrug and Toxin Extrusion Protein‐Mediated Drug‐Drug Interactions in Healthy Volunteers

Recent progress in in vivo phenotyping technologies for better prediction of transporter-mediated drug–drug interactions

(2020) Kazuya Maeda   Drug Metabolism and Pharmacokinetics

Clinical Aspects of Transporter-Mediated Drug-Drug Interactions

(2019) Arne Gessner et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A Clinical DDI Study Assessing a Novel Drug Transporter Phenotyping Cocktail with Adefovir, Sitagliptin, Metformin, Pitavastatin and Digoxin

(2019) Christina Trueck et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI

(2019) Nicholas S. Jones et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Elucidation of N1-methyladenosine as a potential surrogate biomarker for drug interaction studies involving renal organic cation transporters

(2019) Takeshi Miyake et al.   DRUG METABOLISM AND DISPOSITION

Dose‐Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs

(2019) Daiki Mori et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Organic Cation Transporters in Health and Disease

(2019) Hermann Koepsell   PHARMACOLOGICAL REVIEWS

Pragmatic Use of Kidney Function Estimates for Drug Dosing: The Tide Is Turning

(2018) Joanna Q. Hudson et al.   ADVANCES IN CHRONIC KIDNEY DISEASE

Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug-drug interactions

(2018) Peter Stopfer et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Quantitative analysis of elevation of serum creatinine via renal transporter inhibition by trimethoprim in healthy subjects using physiologically-based pharmacokinetic model

(2018) Tomohisa Nakada et al.   Drug Metabolism and Pharmacokinetics

Comparative Study of the Dose-Dependence of OATP1B Inhibition by Rifampicin Using Probe Drugs and Endogenous Substrates in Healthy Volunteers

(2018) Issey Takehara et al.   PHARMACEUTICAL RESEARCH

Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium

(2018) Xiaoyan Chu et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Evidence for the Validity of Pyridoxic Acid (PDA) as a Plasma-Based Endogenous Probe for OAT1 and OAT3 Function in Healthy Subjects

(2018) Hong Shen et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Evaluation of Renal Transporter Inhibition Using Creatinine as a Substrate In Vitro to Assess the Clinical Risk of Elevated Serum Creatinine

(2017) Sumathy Mathialagan et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

In Vitro – In Vivo Extrapolation of Metabolism- and Transporter-Mediated Drug–Drug Interactions—Overview of Basic Prediction Methods

(2017) Kenta Yoshida et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Transporters affecting biochemical test results: Creatinine-drug interactions

(2016) X Chu et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics

(2016) David J. Wagner et al.   PHARMACOLOGICAL RESEARCH

Validation of a total IC50 method which enables in vitro assessment of transporter inhibition under semi-physiological conditions

(2016) Ryota Kikuchi et al.   XENOBIOTICA

Inhibition of the multidrug and toxin extrusion (MATE) transporter by pyrimethamine increases the plasma concentration of metformin but does not increase antihyperglycaemic activity in humans

(2015) J. Oh et al.   DIABETES OBESITY & METABOLISM

N1-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin–trimethoprim interaction

(2014) Fabian Müller et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Conformational Change in Transfer RNA Is an Early Indicator of Acute Cellular Damage

(2014) E. Mishima et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

An atlas of genetic influences on human blood metabolites

(2014) So-Youn Shin et al.   NATURE GENETICS

Organic Cation Transporter OCTs (SLC22) and MATEs (SLC47) in the Human Kidney

(2013) Hideyuki Motohashi et al.   AAPS Journal

Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine

(2013) Fabian Müller et al.   BIOCHEMICAL PHARMACOLOGY

Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters

(2013) Barbara Grün et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Transporter-Mediated Drug–Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies

(2012) K Yoshida et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

N-Methylnicotinamide Is an Endogenous Probe for Evaluation of Drug–Drug Interactions Involving Multidrug and Toxin Extrusions (MATE1 and MATE2-K)

(2012) S Ito et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effect of the Fluoroquinolone Antibacterial Agent DX-619 on the Apparent Formation and Renal Clearances of 6β-Hydroxycortisol, an Endogenous Probe for CYP3A4 Inhibition, in Healthy Subjects

(2012) Yuichiro Imamura et al.   PHARMACEUTICAL RESEARCH

Effects of a MATE Protein Inhibitor, Pyrimethamine, on the Renal Elimination of Metformin at Oral Microdose and at Therapeutic Dose in Healthy Subjects

(2011) H Kusuhara et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Aldehyde Oxidase-Catalyzed Metabolism of N1-Methylnicotinamide in Vivo and in Vitro in Chimeric Mice with Humanized Liver

(2008) S. Kitamura et al.   DRUG METABOLISM AND DISPOSITION